PML risk stratification using anti-JCV antibody index and L-selectin.

@article{Schwab2016PMLRS,
  title={PML risk stratification using anti-JCV antibody index and L-selectin.},
  author={Nicholas Schwab and Tilman Schneider-Hohendorf and B{\'e}atrice SL Pignolet and Michela Spadaro and Dennis G{\"o}rlich and Ingrid Meinl and Susanne Windhagen and Bjoern Tackenberg and Johanna Breuer and Ester Cant{\'o} and Tania Kuempfel and Reinhard Hohlfeld and Volker Siffrin and Felix Luessi and Anita Posevitz-Fejf{\'a}r and Xavier Montalban and Sven G. Meuth and Frauke Zipp and Ralf Gold and Renaud A. Du Pasquier and C. Kleinschnitz and Annett Marita Jacobi and Manuel Comabella and Antonio Bertolotto and David Brassat and Heinz Wiendl},
  journal={Multiple sclerosis},
  year={2016},
  volume={22 8},
  pages={1048-60}
}
BACKGROUND Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters. OBJECTIVE This study aimed at verifying and integrating both parameters into one algorithm for risk stratification. METHODS… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 23 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

The effect of disease modifying therapies on CD62L expression in multiple sclerosis

Multiple sclerosis journal - experimental, translational and clinical • 2018
View 10 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Anti-JC virus (JCV) antibody index differentiates risk of PML in natalizumab-treated MS patients with no prior immunosuppressant use: An updated analysis

G. Kuesters
Neurology • 2015

CD62L (L-selectin) is not a reliable biomarker for predicting risk of PML in natalizumabtreated MS patients

L. Lieberman
Neurology • 2015

Similar Papers

Loading similar papers…